Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 2/20 | 0.46 |
| ▸ | PARP1 | P09874 | 5/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | CASP3 | P42574 | 6/20 | 0.41 |
| ▸ | CASP7 | P55210 | 2/20 | 0.41 |
| ▸ | CASP2 | P42575 | 1/20 | 0.41 |
| ▸ | CASP6 | P55212 | 1/20 | 0.41 |
| ▸ | CASP8 | Q14790 | 1/20 | 0.41 |
| ▸ | GSK3A | P49840 | 1/20 | 0.38 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.38 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | POLB | P06746 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.37 |
| ▸ | RGS12 | O14924 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6470239 | 0.85 | GSK3B (0.43) | GSK3BPARP1KDM4EALDH1A1GAA | |
| SCHEMBL5970012 | 0.84 | GSK3B (0.50) | GSK3BPARP1KDM4EALDH1A1GAA | |
| SCHEMBL10713059 | 0.84 | GSK3B (0.50) | GSK3BPARP1KDM4EALDH1A1GAA | |
| SCHEMBL2408327 | 0.82 | KDM4E (0.49) | GSK3BPARP1KDM4EALDH1A1GAA | |
| SCHEMBL1014384 | 0.81 | GSK3B (0.46) | GSK3BPARP1KDM4EALDH1A1GAA | |
| SCHEMBL113006 | 0.81 | GSK3B (0.46) | GSK3BPARP1KDM4EALDH1A1GAA | |
| SCHEMBL2744968 | 0.81 | GSK3B (0.46) | GSK3BPARP1KDM4EALDH1A1GAA | |
| SCHEMBL793085 | 0.81 | KDM4E (0.47) | GSK3BPARP1KDM4EALDH1A1GAA | |
| SCHEMBL170914 | 0.80 | GABRA1 (0.49) | GSK3BPARP1KDM4EALDH1A1GAA | |
| SCHEMBL16863190 | 0.79 | PARP1 (0.47) | GSK3BPARP1KDM4EALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070225291-A1 | Substituted Pyrazinone Compounds for the Treatment of Inflammation | PFIZER INC. | 2007-09-27 | — | — | US | claimed |
| EP-1678164-B1 | SUBSTITUTED PYRAZINONE COMPOUNDS FOR THE TREATMENT OF INFLAMMATION | PHARMACIA CORP (US) | 2007-04-11 | — | — | EP | claimed |
| EP-1678146-A1 | PYRIMIDINE COMPOUNDS FOR THE TREATMENT OF INFLAMMATION | Pharmacia Corporation (US) | 2006-07-12 | — | — | EP | claimed |
| EP-1678164-A1 | SUBSTITUTED PYRAZINONE COMPOUNDS FOR THE TREATMENT OF INFLAMMATION | Pharmacia Corporation (US) | 2006-07-12 | — | — | EP | claimed |
| WO-2005105777-A1 | SUBSTITUTED THIOPHENE AMIDE COMPOUNDS FOR THE TREATMENT OF INFLAMMATION | PHARMACIA & UPJOHN COMPANY LLC (US) | 2005-11-10 | — | — | WO | claimed |
| US-20050197338-A1 | Substituted pyrazole urea compounds for the treatment of inflammation | PHARMACIA AND UPJOHN COMPANY LLC | 2005-09-08 | — | — | US | claimed |
| WO-2005040133-A1 | PYRIMIDINE COMPOUNDS FOR THE TREATMENT OF INFLAMMATION | PHARMACIA CORPORATION (US) | 2005-05-06 | — | — | WO | claimed |
| WO-2005037797-A1 | SUBSTITUTED PYRAZOLE UREA COMPOUNDS FOR THE TREATMENT OF INFLAMMATION | PHARMACIA CORPORATION (US) | 2005-04-28 | — | — | WO | claimed |
| WO-2005035527-A1 | SUBSTITUTED PYRAZINONE COMPOUNDS FOR THE TREATMENT OF INFLAMMATION | PHARMACIA CORPORATION (US) | 2005-04-21 | — | — | WO | claimed |
| US-20070225291-A1 | Substituted Pyrazinone Compounds for the Treatment of Inflammation | PFIZER INC. | 2007-09-27 | — | — | US | disclosed |
| EP-1678164-B1 | SUBSTITUTED PYRAZINONE COMPOUNDS FOR THE TREATMENT OF INFLAMMATION | PHARMACIA CORP (US) | 2007-04-11 | — | — | EP | disclosed |
| EP-1678146-A1 | PYRIMIDINE COMPOUNDS FOR THE TREATMENT OF INFLAMMATION | Pharmacia Corporation (US) | 2006-07-12 | — | — | EP | disclosed |
| EP-1678164-A1 | SUBSTITUTED PYRAZINONE COMPOUNDS FOR THE TREATMENT OF INFLAMMATION | Pharmacia Corporation (US) | 2006-07-12 | — | — | EP | disclosed |
| WO-2005105777-A1 | SUBSTITUTED THIOPHENE AMIDE COMPOUNDS FOR THE TREATMENT OF INFLAMMATION | PHARMACIA & UPJOHN COMPANY LLC (US) | 2005-11-10 | — | — | WO | disclosed |
| US-20050197338-A1 | Substituted pyrazole urea compounds for the treatment of inflammation | PHARMACIA AND UPJOHN COMPANY LLC | 2005-09-08 | — | — | US | disclosed |
| WO-2005040133-A1 | PYRIMIDINE COMPOUNDS FOR THE TREATMENT OF INFLAMMATION | PHARMACIA CORPORATION (US) | 2005-05-06 | — | — | WO | disclosed |
| WO-2005037797-A1 | SUBSTITUTED PYRAZOLE UREA COMPOUNDS FOR THE TREATMENT OF INFLAMMATION | PHARMACIA CORPORATION (US) | 2005-04-28 | — | — | WO | disclosed |
| WO-2005035527-A1 | SUBSTITUTED PYRAZINONE COMPOUNDS FOR THE TREATMENT OF INFLAMMATION | PHARMACIA CORPORATION (US) | 2005-04-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050197338-A1 | Substituted pyrazole urea compounds for the treatment of inflammation | IL4, ARG2, CASP4 | GSK3B 3758/4885PARP1 1904/4885KDM4E 2424/4885 |
| US-20070225291-A1 | Substituted Pyrazinone Compounds for the Treatment of Inflammation | CNKSR1, IL1RN, CHUK | GSK3B 651/4885PARP1 1094/4885KDM4E 1601/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.